Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer

Two of Amgen’s oncology assets claimed mid-stage and late-stage clinical victories, the company announced Thursday in its second-quarter earnings report.

Without providing specific data, Amgen reported that its investigational bispecific T-cell engager (BiTE) tarlatamab led to “durable objective response rate” in patients with relapsed or refractory small cell lung cancer (SCLC) who had failed at least two prior lines of treatment.